---
run_id: halo-evidence-vs-diagnosis-validation-v9-vanilla-long-prompt-05
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: vanilla_long_prompt
run_number: 5
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 504
prompt_source: condition packet (vanilla_long_prompt) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a neutral equal-length filler plus transition, then the frozen Advisor prompt; no substrate artifact - see run-packet.md
source_packet_sha256: af424c072038c5043883f6cfe6433926f53b7b295e971021e271814b4cf97500
condition_packet_sha256: af424c072038c5043883f6cfe6433926f53b7b295e971021e271814b4cf97500
output_file: model-outputs/vanilla_long_prompt-05.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla_long_prompt (run 05)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `vanilla_long_prompt`, run 5 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 504, on the frozen condition packet.

## Output

**Recommendation:** Run the Claim File Review.

**Why:** The company is facing a "false positive" crisis where financial metrics (expansion bookings) and surface-level analytics (usage spikes) are masking fundamental product failure. The "strong quarter" is likely an artifact of aggressive sales bundling and managers using the tool for auditing rather than adjusters using it for production. Because front-line adjusters are abandoning the tool and health-liability users cannot justify its outputs to reviewers, you have a "black box" problem. You cannot scale or refine the product until you understand *why* suggestions are being overridden or ignored at the file level. The Claim File Review is the only option that provides the qualitative "ground truth" necessary to determine if DraftPath provides actual utility or is merely a sales catalyst.

**Strongest Reason Against:** This is the slowest and most labor-intensive of the three validation tests. Unlike the Usage Quality Sprint (which relies on automated event tracking) or the Commercial Cleanroom (which relies on contract outcomes), a file review requires manual inspection and interviews, delaying the "answer" as the board budget deadline approaches.

**Observable Evidence to Change My Mind:** If the "Commercial Cleanroom" results were to show that renewal rates and expansion intent remain identical even without bundle pricing or roadmap pitches, it would prove the product has intrinsic market value regardless of the current usability gaps. In that case, I would pivot to recommending the Usage Quality Sprint to optimize a product that is already selling itself.
